newsfilter
← Latest News
GlobeNewswire·

Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotech